PATENT CLAIM ANALYSIS

Application Number: 15745230
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-10
Patent Classification: ["424", "178100"]

Abstract:
The present invention belongs to the field of tumor therapy and molecular immunology, and relates to a PDL-1 antibody, a pharmaceutical composition thereof and use thereof. In particular, the present invention relates to a PDL-1 monoclonal antibody or an antigen-binding fragment thereof, wherein the monoclonal antibody has a heavy chain variable region comprising CDRs as set forth in SEQ ID NOs: 15-17; and/or has a light chain variable region comprising CDRs as set forth in SEQ ID NOs: 18-20. The monoclonal antibody of the present invention can bind to PDL-1 specifically, and specifically remove immunosuppressive function of PDL-1 and activate T lymphocytes.

Claim (Index 10):
The monoclonal antibody or an antigen-binding fragment thereof according to  claim 1 , wherein the monoclonal antibody is produced by hybridoma cell strain LT005, and the hybridoma cell strain LT005 is deposited in China Center for Type Culture Collection (CCTCC), and the accession number is CCTCC NO: C2015133.

Metadata:
- Claim Count in Document: 132.0
- Percentile: 86.0
- Lexical Diversity: 1.88333
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15500744', '15761262', '14603808', '13297783', '12738883']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.752442623093015
- 35 USC 102 Novelty (BERT): 0.5577704249711128
- Combined Prediction Score: 0.7329754032808248
- Mean Citation Score: 370.982902
- Max Citation Score: 441.19925
- Similarity Product: 326.2449860310555

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test